Maria Lamar

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 550 citations

Medicine, Oncology, Pharmacology +9

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

Armando Santoro, Matteo Simonelli, Paolo Andrea Zucali et al. · British Journal of Cancer · 2013 · 76 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Lorenza Rimassa, Giovanni Abbadessa, Nicola Personeni et al. · Oncotarget · 2016 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Igor Puzanov, Jeffrey A. Sosman, Armando Santoro et al. · Investigational New Drugs · 2014 · 57 citations · Full text

Pharmacy, Oncology, Pharmacology +17